Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma

The purpose of this study was to define the maximum tolerated dose of erlotinib and characterize its pharmaco-kinetics and safety profile, alone and with temozolomide, with and without enzyme-inducing antiepileptic drugs (EIAEDs), in patients with malignant gliomas. Patients with stable or progressi...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Neuro-oncology (Charlottesville, Va.) Va.), 2006-01, Vol.8 (1), p.67-78
Hauptverfasser:	Prados, Michael D, Lamborn, Kathleen R, Chang, Susan, Burton, Eric, Butowski, Nicholas, Malec, Mary, Kapadia, Ami, Rabbitt, Jane, Page, Margaretta S, Fedoroff, Ann, Xie, Dong, Kelley, Sean K
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Anticonvulsants - administration & dosage Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects Brain Neoplasms - drug therapy Clinical Investigations Dacarbazine - administration & dosage Dacarbazine - adverse effects Dacarbazine - analogs & derivatives Dose-Response Relationship, Drug Drug Interactions Erlotinib Hydrochloride Female Glioma - drug therapy Humans Male Maximum Tolerated Dose Middle Aged Neoplasm Recurrence, Local - drug therapy Quinazolines - administration & dosage Quinazolines - adverse effects Quinazolines - pharmacokinetics Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!